12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
The Internal Revenue Service has announced the cost of living adjustments dollar limits applicable t...
Read More >
When you look at the problems of retirement plans, one that gets short shrift is coverage and that i...
Read More >
Another mid-year reminder: California hotels and motels must train all employees on human trafficki...
Read More >
The upcoming term of the U.S. Supreme Court is shaping up to be a busy one with respect to cases ari...
Read More >
Six hundred and eighty workers from seven poultry processing plants across Mississippi were arrested...
Read More >
U.S. Citizenship and Immigration Services (USCIS) announced that until further notice employers shou...
Read More >